Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo for tough leukemias hits snag: trial ends early

NCT ID NCT03404193

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patients newly diagnosed with AML. The goal was to see how many patients achieved remission. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax and decitabine
What this could lead to
If successful, this combination could offer a new treatment option for older or relapsed patients with certain blood cancers, potentially improving remission rates.
What could go wrong
The trial was terminated early, so results are limited. The combination may cause significant side effects, and effectiveness in different patient groups is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia of ambiguous lineage acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm chronic myelomonocytic leukemia mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM CHRONIC MYELOMONOCYTIC LEUKEMIA MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.